Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873777 | 0.94 | NAMPT (0.48) | MEN1KMT2ANAMPTGRIN2BKIT | |
| SCHEMBL13873755 | 0.85 | EPHX2 (0.57) | MEN1KMT2ANAMPTGRIN2BKIT | |
| SCHEMBL13873815 | 0.82 | CYP2C9 (0.49) | NAMPTKITVNN1CYP2C9 | |
| SCHEMBL13873857 | 0.79 | FAAH (0.57) | MEN1KMT2ANAMPTFAAHKIT | |
| SCHEMBL13873771 | 0.79 | EPHX2 (0.57) | NAMPTKITCYP2C9CYP2C19 | |
| SCHEMBL13873763 | 0.78 | EPHX2 (0.61) | NAMPTGRIN2BKITCYP2C9CYP2C19 | |
| SCHEMBL13873686 | 0.78 | MEN1 (0.65) | MEN1KMT2ANAMPTFAAHGRIN2B | |
| SCHEMBL13873789 | 0.78 | EPHX2 (0.59) | NAMPTKITCYP2C9 | |
| SCHEMBL13873833 | 0.78 | CYP2C9 (0.57) | NAMPTKITCYP2C9 | |
| SCHEMBL13873799 | 0.77 | CHRNA7 (0.52) | MEN1KMT2ANAMPTKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | MEN1 4174/4885KMT2A 3145/4885NAMPT 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.